Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
Fucà G, Cohen R, Lonardi S, Shitara K, Elez ME, Fakih M, Chao J, Klempner SJ, Emmett M, Jayachandran P, Bergamo F, García MD, Mazzoli G, Provenzano L, Colle R, Svrcek M, Ambrosini M, Randon G, Shah AT, Salati M, Fenocchio E, Salvatore L, Chida K, Kawazoe A, Conca V, Curigliano G, Corti F, Cremolini C, Overman M, Andre T, Pietrantonio F. Fucà G, et al. Among authors: elez me. J Immunother Cancer. 2022 Feb;10(2):e004001. doi: 10.1136/jitc-2021-004001. J Immunother Cancer. 2022. PMID: 35110358 Free PMC article.
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors.
Pietrantonio F, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Curigliano G, Cremolini C, Ambrosini M, Ros J, Intini R, Nappo F, Damian S, Morano F, Fucà G, Overman M, Miceli R. Pietrantonio F, et al. Among authors: elez me. J Immunother Cancer. 2021 Aug;9(8):e003370. doi: 10.1136/jitc-2021-003370. J Immunother Cancer. 2021. PMID: 34429334 Free PMC article.
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer.
Nasca V, Barretta F, Corti F, Lonardi S, Niger M, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Cremolini C, Ros J, Ambrosini M, Mazzoli G, Intini R, Overman MJ, Miceli R, Pietrantonio F. Nasca V, et al. Among authors: elez me. J Immunother Cancer. 2023 Jan;11(1):e005493. doi: 10.1136/jitc-2022-005493. J Immunother Cancer. 2023. PMID: 36593068 Free PMC article.
New approaches and targets in advanced colorectal cancer.
Macarulla T, Capdevila J, Perez-Garcia J, Ramos FJ, Elez ME, Markman B, Ruiz-Echarri M, Tabernero J. Macarulla T, et al. Among authors: elez me. Eur J Cancer. 2009 Sep;45 Suppl 1:79-88. doi: 10.1016/S0959-8049(09)70019-X. Eur J Cancer. 2009. PMID: 19775607 No abstract available.
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.
Siena S, Van Cutsem E, Li M, Jungnelius U, Romano A, Beck R, Bencardino K, Elez ME, Prenen H, Sanchis M, Sartore-Bianchi A, Tejpar S, Gandhi A, Shi T, Tabernero J. Siena S, et al. Among authors: elez me. PLoS One. 2013 Nov 11;8(11):e62264. doi: 10.1371/journal.pone.0062264. eCollection 2013. PLoS One. 2013. PMID: 24244261 Free PMC article. Clinical Trial.
A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells.
Puig I, Chicote I, Tenbaum SP, Arqués O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espín E, Prat A, Elez ME, Argilés G, Vivancos A, Tabernero J, Rojas S, Palmer HG. Puig I, et al. Among authors: elez me. Clin Cancer Res. 2013 Dec 15;19(24):6787-801. doi: 10.1158/1078-0432.CCR-12-1740. Epub 2013 Oct 29. Clin Cancer Res. 2013. PMID: 24170545
A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases.
Tabernero J, Elez ME, Herranz M, Rico I, Prudkin L, Andreu J, Mateos J, Carreras MJ, Han M, Gifford J, Credi M, Yin W, Agarwal S, Komarnitsky P, Baselga J. Tabernero J, et al. Among authors: elez me. Clin Cancer Res. 2014 May 15;20(10):2793-804. doi: 10.1158/1078-0432.CCR-13-1837. Epub 2014 Mar 14. Clin Cancer Res. 2014. PMID: 24634378 Clinical Trial.
Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.
Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R. Santos C, et al. Among authors: elez me. Mol Cancer Ther. 2017 Sep;16(9):1999-2007. doi: 10.1158/1535-7163.MCT-17-0153. Epub 2017 Jun 16. Mol Cancer Ther. 2017. PMID: 28626084 Free article.
12 results